Aardvark Therapeutics Faces Securities Fraud Lawsuit
Schall, Brown & Schwartz LLP is reminding investors of a class action lawsuit against Aardvark Therapeutics, Inc. concerning alleged misrepresentations about its ARD-101 drug candidate's safety and prospects.
A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud, according to shareholder rights law firm Schall, Brown & Schwartz LLP. The complaint centers on claims that the company made misleading statements regarding the safety profile of its ARD-101 drug candidate and overstated its clinical and commercial prospects.
Investors who purchased Aardvark Therapeutics stock (NASDAQ: AARD) during the period from the company's initial public offering on February 13, 2025, through May 14, 2026, are encouraged to contact the law firm. Schall, Brown & Schwartz LLP is seeking individuals to potentially serve as lead plaintiff in the case, though this is not a requirement to participate in any potential recovery.
The lawsuit asserts that Aardvark Therapeutics provided false and materially misleading public statements. When the truth about the drug candidate's situation emerged, investors reportedly suffered damages. The law firm, which specializes in securities class action litigation, is advising affected shareholders of their rights and the approaching deadline of October 13, 2026, for potential participation.
As the class has not yet been certified, individuals are not yet represented by an attorney. Choosing to take no action will result in remaining an absent class member. The firm encourages those who believe they have been harmed to seek information regarding the litigation.